Table 3.
Studies investigating mitogen-activated protein kinase kinase (MEK) inhibitors in TNBC.
| Phase 1 | Clinical Trial | Treatment | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Phase 2 | Neoadjuvant chemotherapy Docetaxel with or without Selumetinib in patients with TNBC | Selumetinib Doxorubicin Cyclophosphamide Docetaxel | NCT02685657 |
| Early phase 1 | Defining the TNBC kinome response to GSK1120212, MEK inhibitor | GSK1120212 | NCT01467310 |
| Phase 2 | A single arm, phase II study of single agent Trametinib followed by Trametinib in combination with GSK21411795 | Tramedtinib GSK21411795 | NCT01964924 |
| Phase 1 | Safety, pharmacokinetics (PK) of AKT and MEK combination | GSK1120212 GSK21411795 | NCT01138085 |
| Phase 1 | A study to investigate safety, pharmacokinetics and pharmacodynamics of BKM120 plus GSK1120212 | BKM120 GSK1121212 | NCT01155453 |
| Phase 1 | Safety, pharmacokinetics and pharmacodynamics of BKM120 plus MEK162 | BEZ235 MEK162 | NCT01337765 |
| Phase 1 | A phase Ib, Open-label, Multi-center, Dose-escalation, and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 | BKM120 MEK162 | NCT01363232 |